Everything below concerns incretin hormone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
=== Pharmacokinetics === DOPR crosses the blood–brain barrier in rodents. The drug showed the highest brain/plasma ratio among DOM homologues in rodents, whereas 2,5-dimethoxyamphetamine (2,5-DMA) showed the lowest. This was involved in potency differences between the drugs.
===== Consolidation ===== Acute: Alveolar hemorrhage syndromes Acute eosinophilic pneumonia Acute interstitial pneumonia Cryptogenic organizing pneumonia Chronic: Chronic eosinophilic pneumonia Cryptogenic organizing pneumonia Lymphoproliferative disorders Pulmonary alveolar proteinosis Sarcoidosis
== Diagnosis == The clinical diagnosis of BPD can be made through a psychiatric assessment conducted by a mental health professional, ideally a psychiatrist or psychologist. This comprehensive assessment integrates various sources of information to confirm the diagnosis, encompassing the patient's self-reported clinical history, observations made by the clinician during interviews, and corroborative details obtained from family members, friends, and medical records. Patients should be thoroughly assessed for co-morbid mental health conditions, substance use disorders, suicidal ideation, and any self-harming behaviors. An effective approach involves presenting the criteria of the disorder to the individual and inquiring if they perceive these criteria as reflective of their experiences. Involving individuals in the diagnostic process may enhance their acceptance of the diagnosis. Despite the stigma associated with BPD and previous notions of its untreatability, disclosing the diagnosis to individuals is generally beneficial. It provides them with validation and directs them to appropriate treatment options. The psychological evaluation for BPD typically explores the onset and intensity of symptoms and their impact on the individual's quality of life. Critical areas of focus include suicidal thoughts, self-harm behaviors, and any thoughts of harming others. The diagnosis relies on both the individual's self-reported symptoms and the clinician's observations.
Sources: en.wikipedia.org
Following the attacks, Bush's approval rating increased to 90%. On September 20, he addressed the nation and a joint session of Congress regarding the events, the rescue and recovery efforts, and his intended response to the attacks. New York City mayor Rudy Giuliani's highly visible role resulted in praise in New York and nationally. Many relief funds were immediately set up to provide financial assistance to the survivors of the attacks and the victims' families. By the deadline for victims' compensation on September 11, 2003, 2,833 applications had been received from the families of those killed. Contingency plans for the continuity of government and the evacuation of leaders were implemented soon after the attacks. Congress was not told that the United States had been under a continuity of government status until February 2002. In the largest restructuring of the U.S. government in contemporary history, the United States enacted the Homeland Security Act of 2002, creating the U.S. Department of Homeland Security. Congress also passed the USA PATRIOT Act, saying it would help detect and prosecute terrorism and other crimes. Civil liberties groups have criticized the PATRIOT Act, saying it allows law enforcement to invade citizens' privacy and that it eliminates judicial oversight of law enforcement and domestic intelligence. To effectively combat future acts of terrorism, the National Security Agency (NSA) was given broad powers.
Although the demand for fine chemicals on the merchant market has not grown to the extent originally anticipated, fine chemicals still provide opportunities for companies, which are fostering certain critical success factors, namely running fine chemicals as a core business, pursuing niche technologies—primarily biotechnology—and taking advantage of the opportunities offered by the Asian market.
In contrast to pregabalin, food does not significantly affect the Tmax of gabapentin and increases the Cmax of gabapentin by approximately 10%. The Tmax of the instant-release (IR) formulation of gabapentin enacarbil (as active gabapentin) is about 2.1 to 2.6 hours across all doses (350–2,800 mg) with single administration and 1.6 to 1.9 hours across all doses (350–2,100 mg) with repeated administration. Conversely, the Tmax of the extended-release (XR) formulation of gabapentin enacarbil is about 5.1 hours at a single dose of 1,200 mg in a fasted state and 8.4 hours at a single dose of 1,200 mg in a fed state. The Tmax of phenibut has not been reported, but the onset of action and peak effects have been described as occurring at 2 to 4 hours and 5 to 6 hours, respectively, after oral ingestion in recreational users taking high doses (1–3 g).
Larger living areas on the Skylab space station (1973–1974) allowed for an on-board refrigerator and freezer. This allowed perishable and frozen items to be stored, making microgravity the primary obstacle of future missions. When Skylab's solar panels were damaged during its launch and the station had to rely on minimal power from the Apollo Telescope Mount until Skylab 2 crewmembers performed repairs, the refrigerator and freezer were among the systems that Mission Control kept operational. The Orbital Work Shop (OWS) module had a specially designed wardroom dedicated for food preparation and dining (see image on the right). A dining table was also available, and was designed to avoid hierarchical positions through its triangular layout and to support social cohesion. The table and chairs were fastened to the floor and fitted with foot and thigh restraints, allowing for a more normal eating experience. The trays used could warm the food, and had magnets to hold eating utensils and scissors used for opening food containers. It could accommodate all three crew members at the same time using a variety of microgravity restraints. As a result of the improved eating arrangement, astronauts aboard Skylab maintained some of the best nutritional intake recorded.
Sources: en.wikipedia.org
== External South African operations (1978–1984) == Access to Angola provided PLAN with limitless opportunities to train its forces in secure sanctuaries and infiltrate insurgents and supplies across South West Africa's northern border. The guerrillas gained a great deal of leeway to manage their logistical operations through Angola's Moçâmedes District, using the ports, roads, and railways from the sea to supply their forward operating bases. Soviet vessels offloaded arms at the port of Moçâmedes, which were then transshipped by rail to Lubango and from there through a chain of PLAN supply routes snaking their way south towards the border. "Our geographic isolation was over," Nujoma commented in his memoirs. "It was as if a locked door had suddenly swung open...we could at last make direct attacks across our northern frontier and send in our forces and weapons on a large scale." In the territories of Ovamboland, Kaokoland, Kavangoland and East Caprivi after 1976, the SADF installed fixed defences against infiltration, employing two parallel electrified fences and motion sensors. The system was backed by roving patrols drawn from Eland armoured car squadrons, motorised infantry, canine units, horsemen and scrambler motorcycles for mobility and speed over rough terrain; local San trackers, Ovambo paramilitaries, and South African special forces. PLAN attempted hit-and-run raids across the border but, in what was characterised as the "corporal's war", SADF sections largely intercepted them in the Cutline before they could get any further into South West Africa itself.
nonsense mutation Also point-nonsense mutation. A type of point mutation which results in a premature stop codon in the transcribed mRNA sequence, thereby causing the premature termination of translation, which results in a truncated, incomplete, and often non-functional protein.
=== Addition to alkenes and alkynes === The Hg2+ center binds to alkenes, inducing the addition of hydroxide and alkoxide. For example, treatment of methyl acrylate with mercuric acetate in methanol gives an α-mercuri ester:
=== 9 July === Two people were killed by Russian airstrikes in Odesa Oblast. One person was killed by shelling in Nikopol. Russian forces claimed to have taken the village of Yasnobrodivka, 45 kilometers from Pokrovsk. Russia claimed to have shot down 38 drones over Belgorod, Voronezh, Astrakhan, Kursk, and Rostov Oblasts. An oil depot was set on fire in Kalach-na-Donu, Volgograd Oblast, along with two power substations. Russian sources claimed one killed and two injured in Belgorod Oblast. Ukrainian drones struck a Russian missile testing facility at Kapustin Yar. Russian officials claimed more than 20 drones were shot down, while one drone crashed landed in a field. Subsequent satellite images showed scorch marks at the facility. The United States Department of Justice announced that it had shut down 968 bot accounts on social media, particularly on X, that were operated by Russia and were used to spread pro-Russian and anti-Ukrainian misinformation through the usage of fictional American citizens.
== PAD subtypes == PADs are found in chordates but not in lower animals. In mammals five PAD isotypes – PAD1, PAD2, PAD3, PAD4 and PAD6 – have been found. PAD5 was thought to be a unique isotype in humans, however it was shown to be homologous to PAD4. These isotypes differ in terms of their tissue and cellular distributions. PAD1 expression has been detected in epidermis and the uterus, and it acts in citrullination of keratin and filaggrin, key components of keratinocytes. PAD2 is expressed at a high level in the central nervous system, including the eye and brain, as well as skeletal muscle and the spleen. PAD transcripts have been found in the C57BL6/J mouse eyes as early as embryonic day 14.5. PAD2 has also been shown to interact with vimentin in skeletal muscle and macrophages, causing the filaments to disassemble, suggesting a role in apoptosis. One of PAD2's target substrates is myelin basic protein. In the normal retina, deimination is found in nearly all the retinal layers, including the photoreceptors. Deimination has been also reported in neuronal cells, such as astrocytes, microglia and oligodendrocytes, Schwann cells and neurons. Methylation and phosphorylation of myelin basic protein are active during the process of myelinogenesis. In early development of the central nervous system of the embryo, deimination of myelin basic protein plays a major role in myelin assembly. In adults, deimination myelin basic protein occurs in demyelinating diseases such as multiple sclerosis. Myelin basic protein may affect different cell types in each case.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.